Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
76 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted pipeline therapeutics. The report provides comprehensive information on the Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - The report reviews Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics and enlists all their major and minor projects - The report assesses Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Overview 7 Therapeutics Development 8 Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Stage of Development 8 Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Therapy Area 9 Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Indication 10 Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Companies 13 Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 17 Assessment by Molecule Type 19 Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Companies Involved in Therapeutics Development 21 AbbVie Inc 21 Abeome Corporation 22 Affibody AB 23 Cell Medica Limited 24 Eli Lilly and Company 25 Johnson & Johnson 26 Merck KGaA 27 Novartis AG 28 Orega Biotech SAS 29 Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Drug Profiles 30 ABT-122 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 ABY-035 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 CNTO-6785 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 DLX-2882 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 DLX-2907 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 DLX-2909 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 ixekizumab - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 M-1095 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Monoclonal Antibody to Inhibit IL-17A for Psoriasis and Inflammation - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 OREG-203 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 secukinumab - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Dormant Projects 60 Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Discontinued Products 61 Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Featured News & Press Releases 62 Aug 04, 2016: NICE draft guidance recommends new drug for people with ankylosing spondylitis 62 Jun 21, 2016: Health Canada approval of Taltz (ixekizumab) Brings Targeted Therapy to Canadians Living with Moderate-to-Severe Plaque Psoriasis 62 Jun 09, 2016: New drug clears psoriasis in clinical trials 64 Jun 08, 2016: Studies Demonstrate Lilly's Taltz (Ixekizumab) Maintained Or Achieved High Levels Of Skin Clearance For Patients With Moderate-To-Severe Plaque Psoriasis Through 60 Weeks: Results Published In The New England Journal Of Medicine 65 Jun 08, 2016: Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016 66 Jun 07, 2016: Eli Lilly and Company Announces Data on Ixekizumab At Annual European Congress Of Rheumatology 67 Jun 07, 2016: Tampa Dermatologist Launches Clinical Trial for Psoriatic Arthritis Patients 68 Jun 02, 2016: AbbVie Announces Presentation on ABT-122 at the Annual European Congress of Rheumatology 68 May 04, 2016: Affibody Announces Initial Results from a Phase I Study of ABY-035 69 May 02, 2016: Lilly's Taltz (Ixekizumab) Now Available In The U.S. For The Treatment Of Moderate-To-Severe Plaque Psoriasis 69 Apr 27, 2016: COSENTYX - first Interleukin-17A inhibitor for psoriatic arthritis and ankylosing spondylitis approved by Health Canada 71 Apr 26, 2016: Lilly announces European Commission approval for plaque psoriasis drug 71 Apr 23, 2016: OptiMed Specialty Pharmacy to Distribute Cosentyx 72 Apr 05, 2016: Diplomat Announces TALTZ Availability for the Treatment of Plaque Psoriasis 72 Mar 22, 2016: Lilly's Taltz (Ixekizumab) Receives U.S. FDA Approval For The Treatment Of Moderate-To-Severe Plaque Psoriasis 73 Appendix 75 Methodology 75 Coverage 75 Secondary Research 75 Primary Research 75 Expert Panel Validation 75 Contact Us 75 Disclaimer 76
List of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Products, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Products under Development by Companies, H2 2016 14 Assessment by Monotherapy/Combination Products, H2 2016 15 Number of Products by Stage and Mechanism of Action, H2 2016 16 Number of Products by Stage and Route of Administration, H2 2016 18 Number of Products by Stage and Molecule Type, H2 2016 20 Pipeline by AbbVie Inc, H2 2016 21 Pipeline by Abeome Corporation, H2 2016 22 Pipeline by Affibody AB, H2 2016 23 Pipeline by Cell Medica Limited, H2 2016 24 Pipeline by Eli Lilly and Company, H2 2016 25 Pipeline by Johnson & Johnson, H2 2016 26 Pipeline by Merck KGaA, H2 2016 27 Pipeline by Novartis AG, H2 2016 28 Pipeline by Orega Biotech SAS, H2 2016 29 Dormant Projects, H2 2016 60 Discontinued Products, H2 2016 61
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
